[149] demonstrated that rehydration with the dipeptide contributes in maintaining basketball skill performance and visual reaction time
Some individuals may experience improved sleep due to reduced appetite and better blood sugar control
Key Takeaways on Wegovy Insurance Coverage FDA-approved for weight management : Wegovy (semaglutide 2.4mg) is approved for chronic weight management in adults with BMI 30, or BMI 27 with at least one weight-related comorbidity Commercial insurance coverage is expanding : About 40-50% of employer-sponsored plans now cover GLP-1 medications for weight loss, up from under 20% in 2023 Medicare does NOT cover Wegovy for weight loss : Federal law prohibits Medicare Part D from covering drugs prescribed solely for weight management no exceptions List price without insurance : Approximately $1,349/month ($16,188/year) at retail pharmacy Savings programs available : Novo Nordisk offers a savings card reducing cost to as low as $0-$25/month for eligible commercially insured patients Wegovy is a once-weekly injectable prescription medication containing semaglutide at the 2.4mg dose, manufactured by Novo Nordisk
Why it matters: Different studies require different sample volumes
However, among the common gastrointestinal side effectsincluding nausea, vomiting, diarrhea, and constipationnausea consistently appears as the most frequently reported symptom
At clinical trial dosing of 8 to 12mg per week, research peptide costs translate to roughly $150 to $500 per month
